186 related articles for article (PubMed ID: 25173583)
1. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.
Tsoref D; Welch S; Lau S; Biagi J; Tonkin K; Martin LA; Ellard S; Ghatage P; Elit L; Mackay HJ; Allo G; Tsao MS; Kamel-Reid S; Eisenhauer EA; Oza AM
Gynecol Oncol; 2014 Nov; 135(2):184-9. PubMed ID: 25173583
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.
Oza AM; Pignata S; Poveda A; McCormack M; Clamp A; Schwartz B; Cheng J; Li X; Campbell K; Dodion P; Haluska FG
J Clin Oncol; 2015 Nov; 33(31):3576-82. PubMed ID: 26077241
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.
Oza AM; Elit L; Tsao MS; Kamel-Reid S; Biagi J; Provencher DM; Gotlieb WH; Hoskins PJ; Ghatage P; Tonkin KS; Mackay HJ; Mazurka J; Sederias J; Ivy P; Dancey JE; Eisenhauer EA
J Clin Oncol; 2011 Aug; 29(24):3278-85. PubMed ID: 21788564
[TBL] [Abstract][Full Text] [Related]
5. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
[TBL] [Abstract][Full Text] [Related]
6. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.
Colombo N; McMeekin DS; Schwartz PE; Sessa C; Gehrig PA; Holloway R; Braly P; Matei D; Morosky A; Dodion PF; Einstein MH; Haluska F
Br J Cancer; 2013 Mar; 108(5):1021-6. PubMed ID: 23403817
[TBL] [Abstract][Full Text] [Related]
7. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
[TBL] [Abstract][Full Text] [Related]
8. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
Goodwin RA; Jamal R; Tu D; Walsh W; Dancey J; Oza AM; Elit L; Eisenhauer EA
Gynecol Oncol; 2013 Nov; 131(2):315-20. PubMed ID: 23938374
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Slomovitz BM; Jiang Y; Yates MS; Soliman PT; Johnston T; Nowakowski M; Levenback C; Zhang Q; Ring K; Munsell MF; Gershenson DM; Lu KH; Coleman RL
J Clin Oncol; 2015 Mar; 33(8):930-6. PubMed ID: 25624430
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
Slomovitz BM; Lu KH; Johnston T; Coleman RL; Munsell M; Broaddus RR; Walker C; Ramondetta LM; Burke TW; Gershenson DM; Wolf J
Cancer; 2010 Dec; 116(23):5415-9. PubMed ID: 20681032
[TBL] [Abstract][Full Text] [Related]
11. Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.
Seiler M; Ray-Coquard I; Melichar B; Yardley DA; Wang RX; Dodion PF; Lee MA
Clin Breast Cancer; 2015 Feb; 15(1):60-5. PubMed ID: 25239224
[TBL] [Abstract][Full Text] [Related]
12. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).
Meulenbeld HJ; de Bono JS; Tagawa ST; Whang YE; Li X; Heath KH; Zandvliet AS; Ebbinghaus SW; Hudes GR; de Wit R
Cancer Chemother Pharmacol; 2013 Oct; 72(4):909-16. PubMed ID: 23921574
[TBL] [Abstract][Full Text] [Related]
13. Current phase II clinical data for ridaforolimus in cancer.
Spreafico A; Mackay HJ
Expert Opin Investig Drugs; 2013 Nov; 22(11):1485-93. PubMed ID: 23964772
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer.
Acevedo-Gadea C; Santin AD; Higgins SA; Urva S; Ratner E; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Abu-Khalaf MM
Int J Gynecol Cancer; 2014 Mar; 24(3):528-33. PubMed ID: 24557436
[TBL] [Abstract][Full Text] [Related]
15. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.
Mita MM; Gong J; Chawla SP
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
[TBL] [Abstract][Full Text] [Related]
17. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models.
Squillace RM; Miller D; Cookson M; Wardwell SD; Moran L; Clapham D; Wang F; Clackson T; Rivera VM
Mol Cancer Ther; 2011 Oct; 10(10):1959-68. PubMed ID: 21825008
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
Gupta S; Argilés G; Munster PN; Hollebecque A; Dajani O; Cheng JD; Wang R; Swift A; Tosolini A; Piha-Paul SA
Clin Cancer Res; 2015 Dec; 21(23):5235-44. PubMed ID: 26187616
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
